So if understand correctly, KidneyIntelX was always focused towards late stage as well, so now with PromarkerD entering this space, one can imagine the power of both companies combing the two test into a single test.
I would have classified this as price sensitive given it's just significantly extended the market potential for PromarkerD. Very interesting and also reassuring to see Jannsen still engaged here.
Nice little nugget here too: Given the significant findings for the composite outcomes including cardiovascular death and progression to macroalbuminuria, further studies are warranted to explore the prognostic utility of PromarkerD for additional cardiovascular-specific outcomes.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)